22111Improving Pump Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Challenges and Opportunities

In this program, HF experts will provide insights into mechanisms and clinical evidence for improving myocardial contractility, and emphasize the need for a more personalized treatment of HFrEF to optimize patient outcomes.

A central factor in the pathogenesis of heart failure with reduced ejection fraction (HFrEF) is the initial decrease in systolic function. Pharmacological agents that improve myocardial performance can be categorized based on 3 myocardial mechanisms: calcitropes, which alter intracellular calcium concentrations; myotropes, which affect the molecular motor and scaffolding; and mitotropes, which influence energetics. Omecamtiv mecarbil, an investigational therapy which improves contraction by a novel mechanism of action, has demonstrated a reduction in the risk of a composite of a first heart failure event or cardiovascular death, with an excellent safety and tolerability profile. Greater therapeutic bene t with omecamtiv mecarbil occurs as baseline ejection fraction decreases; this fnding provides a potential opportunity to improve outcomes in a group of patients at greatest risk. New therapies are becoming available for the treatment of HFrEF, providing the HF clinician with more opportunities for an individualized approach to pharmacotherapy. In this program, HF experts will provide insights into mechanisms and clinical evidence for improving myocardial contractility, and emphasize the need for a more personalized treatment of HFrEF to optimize patient outcomes. The in-person symposium will be livestreamed to the HFSA audience who elect to attend virtually. In addition, the program will be available on-demand on the HFSA’s hybrid meeting platform.

Login to your Account